Sparking the future of
targeted cancer treatment
Snipe Medical’s IRE (Irreversible Electroporation) endoscopic ablation catheter system harnesses the power of electricity to target soft tissue lesions, with optimal tumor coverage – shifting targeted cancer treatment with a minimally invasive approach that can be used at any cancer stage, empowering clinicians with expanded treatment options.
Sparking the future of
targeted cancer treatment
Snipe Medical’s IRE (Irreversible Electroporation) endoscopic ablation catheter system harnesses the power of electricity to target soft tissue lesions, with optimal tumor coverage – shifting targeted cancer treatment with a minimally invasive approach that can be used at any cancer stage, empowering clinicians with expanded treatment options.
The Snipe Solution
Snipe Medical empowers physicians at the frontline of cancer treatment with our IRE (Irreversible Electroporation) endoscopic ablation catheter system. Designed for the ablation of soft tissues, Snipe offers clinicians a minimally invasive modality, especially versatile for use across a variety of cancer patient populations, as an adjuvant, neoadjuvant or definitive treatment.
Snipe’s proprietary sensory capacities help optimize cancer treatment with enhanced electrode positioning, while the non-thermal IRE modality enables streamlined, secure ablation of tumors occurring in locations that were previously challenging, such as near critical structures.
This streamlined approach reduces procedure time, lowers costs, and improves patient experience.
The Snipe Advantage:
Targeted, High-Volume Ablation
Diverse Patient
Population
Snipe Medical’s solution can be used for a variety of cancer patients through different stages of cancer, either as a definitive treatment or as neuadjuvant.
Treatment
optimization
Snipe’s proprietary sensory system ensures optimal tumor coverage. This combined with Snipe Medical’s unique design, allows achieving substantial treatment volumes.
Continuum
of Care
Clinicians can now offer treatment alongside diagnosis, keeping patients under their trusted care
Minimally
Invasive
Snipe’s minimally invasive system allows reduced recovery time with minimum side effects, and can lead to better outcomes for patients.
Safe and
Effective
Snipe’s IRE-based system offers a superior safety profile, enabling patients to undergo ablation with confidence, even in cases with tumors near critical structures
Invest in a growing market with a clear roadmap
Snipe Medical is advancing toward FDA approval with a scalable, minimally invasive technology designed to meet the growing demand for safer cancer treatments. With U.S. market entry targeted for 2026, Snipe’s platform offers a clear path to revenue in a growing global oncology market.
We’re seeking investment partners ready to support this transition—from clinical success to commercial scale in a multibillion-dollar global cancer care market.
About Us
Founded in 2021, Snipe Medical is a medtech startup developing precision-targeted ablation solutions for the treatment of solid tumors. Our mission is to transform cancer care by enabling minimally invasive, image-guided therapies that are both highly safe and effective.
Our multidisciplinary team brings together deep expertise in oncology, clinical practice, biomedical engineering, and medical device innovation. With a strong focus on clinical needs and patient outcomes, we are building the next generation of ablation technologies to empower physicians and improve lives.
Ayal Romem, MD,MHA
Scientific Advisor
Snipe’s technology
brings a new level of precision and ease
to lung cancer treatment, offering hope to patients
and a powerful tool for clinicians
Dr. Ayal Romem
Head of Interventional Pulmonology Unit,
Meir Medical Center